Article Sidebar
Published:
Dec 31, 2022Keywords:
Article Details
All materials published in the Babcock University Medical Journal (BUMJ) are protected by the Copyrights Laws of Nigeria. The Authors reserves copyright of their published articles but gives all the users (Authors, Readers, and Researchers) free access to all materials published online under the provisions of the Creative Commons Attribution Non-Commercial 4.0 License. However, permissions are granted to copy, use, and distribute the contents only for non-commercial but academic and scientific purposes with the proviso that the source of the content is appropriately cited and credited.
Main Article Content
The current use of the artemisinin-based Combination Therapies in adult patients at a Tertiary Hospital, South-South Nigeria
Abstract
Objective: The antimalarial preferences, tolerability, and cost of the Artemisinin-based combination therapies (ACTs) among adult patients and caregivers are largely understudied despite being the recommended treatment for Plasmodium falciparum. We, therefore, evaluated antimalarial preferences, tolerability, and cost of the ACTs among adult patients attending the University of Benin Teaching Hospital, Nigeria.
Methods: This was a cross-sectional study conducted among adult patients and their caregivers at the University of Benin Teaching Hospital, Nigeria, using a semi-structured questionnaire. Their preferred antimalarial medication, previous use of antimalarial monotherapies, current ACT use; cost considerations, and adverse effects profile were sought.
Result: Six hundred respondents were recruited with a mean age of 41.4±16.3years and M/F ratio of 1.4. The majority (88.0 %), reported that they had between 1-5 episodes of malaria fever in a year. Only 28.2% received doctors’ prescriptions while 85.8% purchased their antimalarial medications from a pharmacy. Sixty percent of the respondents used at least one ACT; mainly Artemether-Lumefantrine (AL) 312 (52.0%). Only 9.3% reported previous adverse effects with the ACTs with 4.0% of respondents discontinuing their medications. The mean (SD) cost of purchasing ACTs was 1,516.47±760.3 (3.65 USD) Naira.
Conclusion: This study showed adult patients’ preference for the ACTs, especially Artemether-Lumefantrine despite some inclination towards antimalarial monotherapies and parenteral route. There was also a high rate of use of malaria presumptive treatment, but only a few reported adverse effects. There is a need to make ACTs affordable because the cost is still presently high for most Nigerians.
